The Missing Intelligence Layer for Chronic Multi-Morbidity Care
WHOLE-PERSON CLINICAL INTELLIGENCE ACTIVATION PLATFORM
The Missing Intelligence Layer for Chronic Multi-Morbidity Care
WHOLE-PERSON CLINICAL INTELLIGENCE ACTIVATION PLATFORM
chronic multi-morbidity: earlier, faster, costlier
Health systems are not ready
They are stuck in decades-old episodic, disease-centered, transactional infrastructure - in the U.S. and globally
They can't answer three simple questions in one simple view:
- How is 'the whole' patient doing?
- What do we do about it?
- How do we know it worked?
Not ready for Outcomes-Based Reimbursement (OBR)
In 2027, making this gap a balance-sheet liability for every risk-bearing organization.
Zypher.life resolves that gap
Category-defining Initial Product Release, built through $5M Founder-funded corporate venturing R&D
Zypher.life resolves that gap with a simple, defensible, per-condition Whole-Person Health Score-of-Scores, GenAI SOAP Assessment and Plan -- and Agentic One-Click Activation of Physician-approved Plan-of-Care inside existing workflows.
Buyers describe a “negative-click” system that reduces cognitive load and workflow burden while building patient loyalty, reducing leakage, and - in their words - gives “an immediate way to grasp the overall health of the patient and the best path forward.”
The product is built, the IP is owned, and the demand is validated.
No incumbent - EHR, data warehouse, AI assistant, or wellness ring composes a single, per-condition whole-person health score-of-scores of individuals and their lookalike populations.
Demand is not being manufactured: the worldwide search for “Whole Person Care” has grown roughly 5× over the past decade, concentrated in exactly Zypher’s go-to-market geographies, as federal policy institutionalizes the term and clinicians shift to AI at the point of care.
Its anchor adjacency, Population Health Management, is forecast to grow from $85B to $281B by 2030 (22% CAGR).
The international tail is larger still: 2.5B adults with ≥2 conditions, 860M with ≥4, and 400M with ≥6 by 2030.
The ask is a $10M Post-Seed deployed in milestone-based tranches to convert a five-year, $5M founder-funded asset into commercial scale.
Clinical and business CxOs in the U.S., Singapore, India, and China
Told us they need it. They want it,.They have nothing like it.
Want to learn more?
Join us and discover what we can do for you.
The content throughout this website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Forward-looking statements (including projections, trends, and business plans) involve risks and uncertainties, and actual results may differ materially from those expressed or implied. It contains intellectual property of Alphind healthcare and of R&D Ribitzky (c) 2026. All rights reserved. Other brands and names are the property of their respective owners.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.